Pharmaceuticals

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

  SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in bothChina and the U.S. on May 28 2021 and June 11 20...

2021-06-12 11:16 3547

Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress

SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of ...

2021-06-11 13:05 2917

Happiness Biotech Entered Into Electric Vehicle Distribution Agreement With Geely's Subsidiary

NANPING, China, June 10, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...

2021-06-10 21:00 12626

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an agreement granting Nuance Pharma, aShanghai-based specialty pharmaceutical c...

2021-06-10 14:00 2759

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer

SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment ofCharles S. Ryan, JD, PhD as President and Chief Execut...

2021-06-09 21:00 1944

China Pharma to Launch Highly Purified NMN+PQQ Product

HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...

2021-06-09 20:00 10223

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...

2021-06-07 20:00 7199

China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

SHANGHAI, June 3, 2021 /PRNewswire/ -- MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focused on the discovery, development and commercialization of antibacterial agents against drug-resistant bacterial infection, announced that China National Medical Products Admi...

2021-06-03 22:15 2084

Shanghai Asclepius Meditec and International Department of Central Committee of CPC Collaborate to Provide Emergency Support to Fight COVID-19 in Nepal

SHANGHAI, June 2, 2021 /PRNewswire/ -- The President of Asclepius Meditec – the company behind the innovativeHydrogen Oxygen Generator with Nebulizer

2021-06-02 20:00 2126

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate

INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...

2021-06-02 19:00 2118

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

SEOUL, South Korea, June 1, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effect of Enavogliflozin, originally developed as Type II Diabetes Treatment forhumans, on treating canine diabetes were publish...

2021-06-01 21:00 2171

GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII

NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII. GenScript ProBio s...

2021-06-01 21:00 1888

Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials

Highlights: * Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman andPitt Hopkins syndromes * Positive outcome is an important milestone that enables Neuren to proceed with IND...

2021-06-01 18:00 1610

Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services

* Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 * The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish ...

2021-05-31 19:00 2975

Dr. Seungpil Yu will hold a retirement ceremony and conclude his 46-year term as a pharmaceutical executive.

SEOUL, South Korea, May 28, 2021 /PRNewswire/ -- Dr. Seungpil Yu is a living witness to the long history of Yuyu Pharma, which celebrated its 80th anniversary this year, having laid the foundation for Yuyu Pharma to continue to thrive well into its 100th year. While in the United States, Dr. Yu r...

2021-05-28 21:00 3785

Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management

* Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas * Samsung Biologics adds ISO50001, ISO45001, ISO14001 for Energy Management, Occupational Health and ...

2021-05-28 20:00 3439

AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease

SHANGHAI, May 27, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced thatChina's National Medical Products Administrati...

2021-05-28 08:00 2531

Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test

* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage * Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021 * 2nd ODD granted as treatment for systemic sclerosis from the US FDA SEOUL, South Korea, May 27, 2021...

2021-05-27 21:00 1980

Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization

TAIPEI, May 26, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, as a ...

2021-05-27 11:33 3048

TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China

NANJING, China, May 26, 2021 /PRNewswire/ -- TransThera Biosciences Co. Ltd. ( "TransThera" ), a clinical stage biotechnology company dedicated to developing innovative therapeutics across oncology, cardiovascular, and inflammatory diseases with major unmet medical needs globally and inChina,  to...

2021-05-26 21:00 1861